Identification of SPLUNC1's ENaC-Inhibitory Domain Yields Novel Strategies to Treat Sodium Hyperabsorption in 2 Cystic Fibrosis Airway Epithelial Cultures

AJP Lung Cellular and Molecular Physiology (Impact Factor: 4.08). 10/2013; DOI: 10.1152/ajplung.00103.2013


The epithelial sodium channel (ENaC) is responsible for Na+ and fluid absorption across colon, kidney and airway epithelia. Short Palate Lung and Nasal Epithelial Clone 1 (SPLUNC1) is a secreted, innate defense protein and an autocrine inhibitor of ENaC that is highly expressed in airway epithelia. While SPLUNC1 has a bactericidal permeability-increasing protein (BPI)-type structure, its N-terminal region lacks structure. Here we found that an eighteen amino acid peptide, S18, which corresponded to residues G22-A39 of SPLUNC1's N-terminus inhibited ENaC activity to a similar degree as full-length SPLUNC1 (~2.5 fold), whilst SPLUNC1 protein lacking this region was without effect. S18 did not inhibit the structurally related acid-sensing ion channels, indicating specificity for ENaC. However, S18 preferentially bound to the β-ENaC subunit in a glycosylation dependent manner. ENaC hyperactivity is contributory to cystic fibrosis (CF) lung disease. Unlike control, CF human bronchial epithelial cultures (HBECs) where airway surface liquid height (ASL) was abnormally low (4.2 ± 0.6 µm), addition of S18 prevented ENaC-led ASL hyperabsorption and maintained CF ASL height at 7.9 ± 0.6 µm, even in the presence of neutrophil elastase, which is comparable to heights seen in normal HBECs. Our data also indicate that the ENaC inhibitory domain of SPLUNC1 may be cleaved away from the main molecule by neutrophil elastase, suggesting that it may still be active during inflammation or neutrophilia. Furthermore, the robust inhibition of ENaC by the S18 peptide suggests that this peptide may be suitable for treating CF lung disease.

Download full-text


Available from: Omar Alijevic,
42 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Our understanding of mammalian-microbial mutualism has expanded by combing microbial sequencing with evolving molecular and cellular methods, and unique model systems. Here, the recent literature linking the microbiota to diseases of three of the key mammalian mucosal epithelial compartments - nasal, lung and gastrointestinal (GI) tract - is reviewed with a focus on new knowledge about the taxa, species, proteins and chemistry that promote health and impact progression toward disease. The information presented is further organized by specific diseases now associated with the microbiota:, Staphylococcus aureus infection and rhinosinusitis in the nasal-sinus mucosa; cystic fibrosis (CF), chronic obstructive pulmonary disorder (COPD), and asthma in the pulmonary tissues. For the vast and microbially dynamic GI compartment, several disorders are considered, including obesity, atherosclerosis, Crohn's disease, ulcerative colitis, drug toxicity, and even autism. Our appreciation of the chemical symbiosis ongoing between human systems and the microbiota continues to grow, and suggest new opportunities for modulating this symbiosis using designed interventions.
    Journal of Molecular Biology 10/2014; 426(23). DOI:10.1016/j.jmb.2014.09.011 · 4.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: CFTR is a cAMP-activated chloride and bicarbonate channel that is critical for lung homeostasis. Decreases in CFTR expression have dire consequences in cystic fibrosis (CF) and have been suggested to be a component of the lung pathology in Chronic Obstructive Pulmonary Disease (COPD). Decreases or loss of channel function often lead to mucus stasis, chronic bacterial infections, and the accompanying chronic inflammatory responses that promote progressive lung destruction, and eventually in CF, lung failure. Here we discuss CFTR's functional role airway surface liquid hydration and pH, in regulation of other channels such as the epithelial sodium channel, and in regulating inflammatory responses in the lung.
    AJP Lung Cellular and Molecular Physiology 11/2014; 307(12):ajplung.00326.2014. DOI:10.1152/ajplung.00326.2014 · 4.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BPIFA1 and BPIFB1 are putative innate immune molecules expressed in the upper airways. Due to their hypothesized roles in airway defense, these molecules may contribute to lung disease severity in cystic fibrosis (CF). We interrogated BPIFA1/BPIFB1 SNPs in data from an association study of CF modifier genes and found an association of the G allele of rs1078761 with increased lung disease severity (p=2.71 x 10-4). We hypothesized that the G allele of rs1078761 is associated with decreased expression of BPIFA1 and/or BPIFB1. Genome-wide lung gene expression and genotyping data from 1,111 individuals with lung disease, including 51 CF patients, were tested for associations between genotype and BPIFA1 and BPIFB1 gene expression levels. Findings were validated by qPCR in a subset of 77 individuals. Western blotting was used to measure BPIFA1 and BPIFB1 protein levels in 93 lung and 101 saliva samples. The G allele of rs1078761 was significantly associated with decreased mRNA levels of BPIFA1 (p=4.08 x 10-15) and BPIFB1 (p=0.0314). These findings were confirmed with qPCR and western blotting. We conclude that the G allele of rs1078761 may be detrimental to lung function in CF due to decreased levels of BPIFA1 and BPIFB1.
    American Journal of Respiratory Cell and Molecular Biology 01/2015; DOI:10.1165/rcmb.2014-0182OC · 3.99 Impact Factor
Show more